Synthesis, Characterisation and Docking Studies of Thioxoquinoline Derivatives as Potential Anti-Alzheimer Agents. 2022

Shalaka P Naik, and Chandavarkar Sachin, and Phadte Soniya, and Naik Harishchandra, and Sinari Venkatesh, and Tawde Shilpa, and Mamle Desai Shivlingarao
Department of Pharmaceutical Chemistry, P.E. S's Rajaram, and Tarabai Bandekar, College of Pharmacy, Farmagudi, Ponda, Goa, 403 401, India.

Alzheimer's Disease (AD) is related to the total loss of presynaptic neurotransmitters of the cholinergic system in regions of the brain related to memory. Approximately 15% of the population beyond the age of 65 years are suffering from dementia due to AD and the rate is rising exponentially with age. The objective of this research was the synthesis of a series of 1-(4-substituted-2- thioxoquinolin-1(2H)-yl)-2-substituted ethanoneV (a-c(1-4)) by undergoing acetylation at the nitrogen of 4-hydroxyquinolin-2-(1H)-one and replacing its oxygen atom with sulphur moiety via the process of thionation. To carry out-docking studies of the title compounds were carried out using Molegro Virtual Docker (MVD-2013, 6.0) software and in-vitro screening of anti-alzheimer's activity by Ellman assay method. The synthesis of the title compounds was carried out via the sequential reaction from the initial dianilide to ring closure to the substituted quinoline-2-ones using polyphosphoric acid as a cyclising agent. These substituted quinoline-2-ones on thionation by phosphorous pentasulphide in aluminium trioxide gave quinoline-2-thiones and on further condensation with chloroacetyl chloride, they resulted in compounds with a leaving group. Nucleophilic substitution reaction of chloroacetylquinoline- 2-thiones with secondary amines resulted in the title compounds 1-(4-substituted-2- thioxoquinolin-1(2H)-yl)-2-substituted ethanone V(a-c(1-4)). The pharmacophore mapping of synthesized compounds was performed by using Molegro Virtual Docker (MVD-2013,6.0). The title compounds were tested for their in vitro anti-Alzheimer's activity using the Ellman assay method. All the synthesized compounds were characterized by IR, 1H NMR, 13C NMR, and Mass spectral data. Docking studies of all the synthesized compounds were carried out using a structural mechanism for the inhibition of CDK5-p25 by roscovitine, aloisine, and indirubin (PDB ID: 1UNG), showed favourable results, with compound (Vb3) showing a MolDock score of -85.9788 that was comparable to that of the active ligand (ALH_1288 [B]) with MolDock score of - 87.7609. The synthesized derivatives possessed the potential to bind with some of the amino acid residues of the active site. Compound 2-(6-chloro-4-hydroxy-2-thioxoquinolin-1(2H)-yl-1-piperazin- 1-ethanone (Vb3) was found to be the most active among the synthesized derivatives, with IC50 values of 32 ± 0.1681. All the synthesized compounds showed potent to moderate activity in comparison to the reference standard donepezil.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D011804 Quinolines
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077265 Donepezil An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE. 1-Benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine hydrochloride,Aricept,Donepezil Hydrochloride,Donepezilium Oxalate Trihydrate,E 2020,E-2020,E2020,Eranz
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D013871 Thiones Sulfur-containing compounds also known as thioketones of general formula R2C Thioketone,Thione,Thioketones
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Shalaka P Naik, and Chandavarkar Sachin, and Phadte Soniya, and Naik Harishchandra, and Sinari Venkatesh, and Tawde Shilpa, and Mamle Desai Shivlingarao
February 2018, Bioorganic & medicinal chemistry letters,
Shalaka P Naik, and Chandavarkar Sachin, and Phadte Soniya, and Naik Harishchandra, and Sinari Venkatesh, and Tawde Shilpa, and Mamle Desai Shivlingarao
May 2024, Chemistry & biodiversity,
Shalaka P Naik, and Chandavarkar Sachin, and Phadte Soniya, and Naik Harishchandra, and Sinari Venkatesh, and Tawde Shilpa, and Mamle Desai Shivlingarao
February 2024, ACS chemical neuroscience,
Shalaka P Naik, and Chandavarkar Sachin, and Phadte Soniya, and Naik Harishchandra, and Sinari Venkatesh, and Tawde Shilpa, and Mamle Desai Shivlingarao
June 2017, Molecules (Basel, Switzerland),
Shalaka P Naik, and Chandavarkar Sachin, and Phadte Soniya, and Naik Harishchandra, and Sinari Venkatesh, and Tawde Shilpa, and Mamle Desai Shivlingarao
November 2023, Bioorganic chemistry,
Shalaka P Naik, and Chandavarkar Sachin, and Phadte Soniya, and Naik Harishchandra, and Sinari Venkatesh, and Tawde Shilpa, and Mamle Desai Shivlingarao
November 2020, Molecular diversity,
Shalaka P Naik, and Chandavarkar Sachin, and Phadte Soniya, and Naik Harishchandra, and Sinari Venkatesh, and Tawde Shilpa, and Mamle Desai Shivlingarao
May 2016, American journal of Alzheimer's disease and other dementias,
Shalaka P Naik, and Chandavarkar Sachin, and Phadte Soniya, and Naik Harishchandra, and Sinari Venkatesh, and Tawde Shilpa, and Mamle Desai Shivlingarao
June 2011, European journal of medicinal chemistry,
Shalaka P Naik, and Chandavarkar Sachin, and Phadte Soniya, and Naik Harishchandra, and Sinari Venkatesh, and Tawde Shilpa, and Mamle Desai Shivlingarao
April 2022, Microbial pathogenesis,
Shalaka P Naik, and Chandavarkar Sachin, and Phadte Soniya, and Naik Harishchandra, and Sinari Venkatesh, and Tawde Shilpa, and Mamle Desai Shivlingarao
December 2017, Journal of enzyme inhibition and medicinal chemistry,
Copied contents to your clipboard!